To develop a novel and effective anticoagulant with potent and selective factor Xa (FXa) inhibitory activity, a new series of cinnamyl derivatives with enhanced lipophilicity and prodrug forms were synthesized and their biological activities were evaluated. As a result, we found that cinnamyl derivative (N-4-[1-(acetimidoyl)piperidin-4-yloxy]-3-carbamoylphenyl}-N-[(Z)-3-(3-amidinophenyl)-2-fluoro-2-propenyl]sulfamoyl)acetic acid dihydrochloride (26d, R-142086) with a fluorine atom on the double bond exhibited potent anticoagulant activity and no mutagenic potential. Moreover, orally administered R-142086 exhibited potent anti-FXa activity and anticoagulant activity in dogs.
为了开发一种新型有效的抗凝药物,具备强效且选择性的Xa因子(FXa)抑制活性,我们合成了一系列具有增强亲脂性和前药形式的肉桂基衍
生物,并对它们的
生物活性进行了评估。结果发现,带有
氟原子在双键上的肉桂基衍
生物(N-4-[1-(乙
酰亚胺基)
哌啶-4-基氧]-3-羧酰胺苯基}-N-[(Z)-3-(3-
氨基酰苯基)-2-
氟-2-
丙烯基]
磺胺酰)
乙酸二盐酸盐(26d,R-142086)表现出强大的抗凝活性且无致突变潜力。此外,经口给予的R-142086在犬只中展现了强力的抗FXa活性和抗凝活性。